cas 214822-96-5|| where to buy Methyl 4-fluoro-3-hydroxybenzoate

Nom du produit:Methyl 4-fluoro-3-hydroxybenzoate

IUPAC Name:methyl 4-fluoro-3-hydroxybenzoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM155832-100g	in stock	Łřř

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 214822-96-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:214822-96-5; Formule moléculaire:C8H7FO3; Point de fusion:-; Code SMILES:O=C(OC)C1=CC=C(F)C(O)=C1; Densité:

: Numéro de catalogue:CM155832; Poids moléculaire:170.14; Point d'ébullition:268.9°C at 760 mmHg; N° Mdl:MFCD06797457; Stockage:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Acoramidis; In 2023, BridgeBio announced positive results from ATTRibute-CM, a Phase 3 study of acoramidis in ATTR cardiomyopathy (ATTR-CM). For patients with ATTR-CM, TTR stabilization offers the chance to both preserve the cardio-protective benefits of TTR and address the root cause of disease. Acoramidis (AG10) is an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).